RE:RE:AACR PostersWildcard as I said, but the Chinese govt has strategically identified biotech as an area they want to get much larger in, primarily for national health reasons. It seems the model of India becoming huge in generics and moving into primary has pushed them to move quicker from generics to innovation. Part of that is to go find drugs to in-license and promising therapies to trial at home.
If you could find one working in the PD-L1 area doing trials, it probably wouldn't cost a whole lot to add in a combo cohort and see if the lab science works in humans, giving you a huge leg-up if those poster numbers do show a large difference in outcome with the combo. Just have to wait and see the numbers. Nothing to get excited about until there's actual facts around working in humans unfortunately.
Here's from a BCG report in 2020:
https://www.bcg.com/publications/2020/competing-in-chinas-biopharma-market "
INNOVATION WAVE 1.0:
Starting in the early 2000s, a first wave of new generation innovative pharma companies formed in China. Focused on being fast followers for me-too and me-better drugs, they sought new molecules on validated or late-stage clinical targets or combination therapies. As this innovation wave continues, the focus is shifting more toward me-better innovations. For example, more than 50 Chinese companies are focused on PD-1/PD-L12candidates, looking for improved efficacy, safety, and convenience."